Novartis's pelacarsen fails cardiovascular outcomes trial in Phase 3 studySep 4Clinical readoutIonis PharmaceuticalsNovartis
FDA approves Ionis's ZANVASTRO for Alexander diseaseSep 4Regulatory milestoneIonis Pharmaceuticalszilganersen
FDA approval file confirms Zanvastro details for Alexander diseaseSep 3Regulatory decisionIonis Pharmaceuticalszilganersen
Ionis posts Q2 2026 results, flags second-half pipeline milestonesJul 29Quarterly updatedonidalorsenIonis Pharmaceuticals
Sign inSign in